Compare Starbucks Corp (SBUX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Zimmer Biomet Holdings Inc — how do they compare? Starbucks Corp trades at $100.45 (market cap $116.29B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Starbucks Corp is far larger — about 6.5× Zimmer Biomet Holdings Inc's market cap, and Starbucks Corp pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| SBUX | ZBH | |
|---|---|---|
Market Cap | $116.29B | $17.97B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $104.26 |
52-Week Low | $78.46 | $79.58 |
Enterprise Value | $135.12B | $25.04B |
Dividend Yield | 2.43% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish momentum in moving averages but recent earnings beats in Q1 and Q2 2026 highlight operational progress. Revenue reached $37.18B in 2025, though net income margin compressed to 5.17%. Analyst consensus is a Buy with a $113.60 price target, but high P/E of 58.97 suggests premium valuation. Recent news emphasizes CEO Niccol's turnaround efforts and union-related legal developments.
The outlook balances earnings momentum against valuation concerns. Upside hinges on margin recovery and sustained comp sales growth, but risks include labor disputes, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic, with 47.46% of analysts rating Buy.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
